Skip NavigationSkip to Content
Return Return to Search Results

Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer

  1. Author:
    Chen, Xin
    Oppenheim, Joost

  2. Author Address

    Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China.NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA.
    1. Year: 2017
    2. Date: Jan 17
  2. Journal: SCIENCE SIGNALING
  3. AMER ASSOC ADVANCEMENT SCIENCE,
    1. 10
    2. 462
    3. Pages: eaal2328
  5. Type of Article: Article
  6. Article Number: ARTN eaal2328
  7. ISSN: 1945-0877
  1. Abstract:

    Tumor necrosis factor receptor type II (TNFR2) is expressed both by some cancer cells and by tumor-infiltrating immunosuppressive CD4(+)FoxP3(+) regulatory T cells (T-regs). TNFR2 stimulates the activation and proliferation of T-regs, a major checkpoint of antitumor immune responses, and promotes cancer cell survival and tumor growth. In this issue of Science Signaling, Torrey et al. found that dominant antagonistic antibodies against human TNFR2 may be a potential therapy for ovarian cancer patients by simultaneously suppressing T-reg activity and inducing the death of the cancer cells.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1126/scisignal.aal2328
  3. PMID: 28096506
  4. View record in Web of Science®
  5. WOS: 000393784200001

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel